Molecular basis for the inhibition of human NMPRTase, a novel target for anticancer agents

Nature Structural and Molecular Biology

Volumn 13, Issue 7, 2006, Pages 582-588

  Khan, Javed A ^a   Tao, Xiao ^a,b   Tong, Liang ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b ROCKEFELLER UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ASPARTIC ACID; DIMER; NICOTINAMIDE NUCLEOTIDE; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; TRANSFERASE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BINDING SITE; BIOSYNTHESIS; CHEMICAL ANALYSIS; COMPLEX FORMATION; CRYSTAL STRUCTURE; DRUG MECHANISM; ENZYME INHIBITION; ENZYME SPECIFICITY; ENZYME SUBSTRATE; HUMAN; MUTAGENESIS; NONHUMAN; PRIORITY JOURNAL;

ACRYLAMIDES; AMINO ACID SEQUENCE; ANIMALS; ANTINEOPLASTIC AGENTS; CRYSTALLIZATION; HUMANS; KINETICS; MICE; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; PENTOSYLTRANSFERASES; PIPERIDINES; PROTEIN STRUCTURE, SECONDARY; RECOMBINANT PROTEINS; SEQUENCE ALIGNMENT; SEQUENCE HOMOLOGY, AMINO ACID; SUBSTRATE SPECIFICITY;

MURINAE;

EID: 33745817828     PISSN: 15459993     EISSN: 15459985     Source Type: Journal    
DOI: 10.1038/nsmb1105     Document Type: Article

References (41)

1. Ziegler, M. New functions of a long-known molecule. Emerging roles of NAD in cellular signaling. Eur. J. Biochem. 267, 1550-1564 (2000).
2. Guarente, L. & Picard, F. Calorie restriction - the SIR2 connection. Cell 120, 473-482 (2005).
3. +-dependent histone/protein deacetylases. Biochem. Soc. Trans. 32, 904-909 (2004).
4. + homeostasis in man. Cell. Mol. Life Sci. 61, 19-34 (2004).
5. Araki, T., Sasaki, Y. & Milbrandt, J. Increased nuclear NAD biosynthesis and SIRT1 activation prevent axonal degeneration. Science 305, 1010-1013 (2004).
6. Guse, A.H. Second messenger function and the structure-activity relationship of cyclic adenosine diphosphoribose (cADPR). FEBS J. 272, 4590-4597 (2005).
7. Rongvaux, A. et al. Pre-B-cell colony-enhancing factor, whose expression is up-regulated in activated lymphocytes, is a nicotinamide phorphoribosyltransferase, a cytosolic enzyme involved in NAD biosynthesis. Eur. J. Immunol. 32, 3225-3234 (2002).
8. Wosikowski, K. et al. WK175, a novel antitumor agent, decreases the intracellular nicotinamide adenine dinucleotide concentration and induces the apoptotic cascade in human leukemia cells. Cancer Res. 62, 1057-1062 (2002).
9. Hasmann, M. & Schemainda, I. FK866, a highly specific noncompetitive inhibitor of nicotinamide phosphoribosyltransferase, represents a novel mechanism for induction of tumor cell apoptosis. Cancer Res. 63, 7436-7442 (2003).
10. Hufton, S.E. et al. A profile of differentially expressed genes in primary colorectal cancer using suppression substractive hybridization. FEBS Lett. 463, 77-82 (1999).
11. van Beijnum, J.R. et al. Target validation for genomics using peptide-specific phage antibodies: a study of five gene products overexpressed in colorectal cancer. Int. J. Cancer 101, 118-127 (2002).
12. Muruganandham, M. et al. Metabolic signatures associated with a NAD synthesis inhibitor-induced tumor apoptosis identified by 1H-decoupled-31P magnetic resonance spectroscopy. Clin. Cancer Res. 11, 3503-3513 (2005).
13. Drevs, J., Loser, R., Rattel, B. & Esser, N. Antiangiogenic potency of FK866/K22.175, a new inhibitor of intracellular NAD biosynthesis, in murine renal cell carcinoma. Anticancer Res. 23, 4853-4858 (2003).
14. Samal, B. et al. Cloning and characterization of the cDNA encoding a novel human pre-B-cell colony-enhancing factor. Mol. Cell. Biol. 14, 1431-1437 (1994).
15. Fukuhara, A. et al. Visfatin, a protein secreted by visceral fat that mimics the effects of insulin. Science 307, 426-430 (2005).
16. Hug, C. & Lodish, H.F. Visfatin: a new adipokine. Science 307, 366-367 (2005).
17. Sethi, J.K. & Vidal-Puig, A. Visfatin: the missing link between intra-abdominal obesity and diabetes? Trends Mol. Med. 11, 344-347 (2005).
18. Stephens, J.M. & Vidal-Puig, A.J. An update on visfatin/pre-B cell colony-enhancing factor, an ubiquitously expressed, illusive cytokine that is regulated in obesity. Curr. Opin. Lipidol. 17, 128-131 (2006).
19. Kitani, T., Okuno, S. & Fujisawa, H. Growth phase-dependent changes in the subcellular localization of pre-B-cell colony-enhancing factor. FEBS Lett. 544, 74-78 (2003).
20. Eads, J.C., Ozturk, D., Wexler, T.B., Grubmeyer, C. & Sacchettini, J.C. A new function for a common fold: the crystal structure of quinolinic acid phosphoribosyltransferase. Structure 5, 47-58 (1997).
21. Sharma, V., Grubmeyer, C. & Sacchettini, J.C. Crystal structure of quinolinic acid phosphoribosyltransferase from Mycobacterium tuberculosis: a potential TB drug target. Structure 6, 1587-1599 (1998).
22. Shin, D.H. et al. Crystal structure of a nicotinate phosphoribosyltransferase from Thermoplasma acidophilum. J. Biol. Chem. 280, 18326-18335 (2005).
23. Chappie, J.S. et al. The structure of a eukaryotic nicotinic acid phosphoribosyltransferase reveals structural heterogeneity among type II PRTases. Structure 13, 1385-1396 (2005).
24. Hendrickson, W.A. Determination of macromolecular structures from anomalous diffraction of synchrotron radiation. Science 254, 51-58 (1991).
25. Revollo, J.R., Grimm, A.A. & Imai, S.-I. The NAD biosynthesis pathway mediated by nicotinamide phosphoribosyltransferase regulates Sir2 activity in mammalian cells. J. Biol. Chem. 279, 50754-50763 (2004).
26. Gross, J., Rajavel, M., Segura, E. & Grubmeyer, C. Energy coupling in Salmonella typhimurium nicotinic acid phosphoribosyltransferase: identification of His-219 as site of phosphorylation. Biochemistry 35, 3917-3924 (1996).
27. Gross, J.W., Rajavel, M. & Grubmeyer, C. Kinetic mechanism of nicotinic acid phosphoribosyltransferase: implications for energy coupling. Biochemistry 37, 4189-4199 (1998).
28. Hendrickson, W.A., Horton, J.R. & LeMaster, D.M. Selenomethionyl proteins produced for analysis by multiwavelength anomalous diffraction (MAD): a vehicle for direct determination of three-dimensional structure. EMBO J. 9, 1665-1672 (1990).
29. Otwinowski, Z. & Minor, W. Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol. 276, 307-326 (1997).
30. Weeks, C.M. & Miller, R. The design and implementation of SnB v2.0. J. Appl. Crystallogr. 32, 120-124 (1999).
31. Terwilliger, T.C. SOLVE and RESOLVE: automated structure solution and density modification. Methods Enzymol. 374, 22-37 (2003).
32. Collaborative Compuational Project, Number 4. The CCP4 suite: programs for protein crystallography. Acta Crystallogr. D Biol. Crystallogr. 50, 760-763 (1994).
33. Jones, T.A., Zou, J.V., Cowan, S.W. & Kjeldgaard, M. Improved methods for building protein models in electron density maps and the location of errors in these models. Acta Crystallogr. A 47, 110-119 (1991).
34. Brunger, A.T. et al. Crystallography & NMR System: a new software suite for macromolecular structure determination. Acta Crystallogr. D Biol. Crystallogr. 54, 905-921 (1998).
35. Jogi, G., Tao, X., Xu, Y. & Tong, L. COMO: a program for combined molecular replacement. Acta Crystallogr. D Biol. Crystallogr. 57, 1127-1134 (2001).
36. Murshudov, G.N., Vagin, A.A. & Dodson, E.J. Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr. D Biol. Crystallogr. 53, 240-255 (1997).
37. Zhou, T. et al. Structure of human nicotinamide/nicotinic acid mononucleotide adenylyltransferase. Basis for the dual substrate specificity and activation of the oncolytic agent tiazofurin. J. Biol. Chem. 277, 13148-13154 (2002).
38. Jauch, R., Humm, A., Huber, R. & Wahl, M.C. Structures of Escherichia coli NAD synthetase with substrates and products reveal mechanistic rearrangements. J. Biol. Chem. 280, 15131-15140 (2005).
39. + synthetase from Helicobacter pylori. Proteins 58, 985-988 (2005).
40. Carson, M. Ribbon models of macromolecules. J. Mol. Graph. 5, 103-106 (1987).
41. Evans, S.V. SETOR: hardware lighted three-dimensional solid model representations of macromolecules. J. Mol. Graph. 11, 134-138 (1993).